Alta Wealth Advisors’s Biogen BIIB Stock Holding History

Alta Wealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,103	Closed	-$238K	–	121
2024 Q1	$238K	Sell	1,103 -112	-9%	-$26.2K	0.12%	118
2023 Q4	$314K	Sell	1,215 -720	-37%	-$177K	0.18%	105
2023 Q3	$497K	Buy	1,935 +125	+7%	+$33.4K	0.3%	85
2023 Q2	$516K	Buy	1,810 +262	+17%	+$78K	0.3%	89
2023 Q1	$430K	Buy	+1,548	New	+$428K	0.27%	98

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alta Wealth Advisors's BIIB Position: Q2 2024 in Review

Alta Wealth Advisors sold out of Biogen (BIIB) in Q2 2024, closing a stake of 1,103 shares — an estimated $238K sold.

Alta Wealth Advisors first reported a position in BIIB in Q1 2023 and held it in 5 quarters. The position peaked at $516K in Q2 2023. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Alta Wealth Advisors reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Alta Wealth Advisors sold 1,103 Biogen shares in Q2 2024, an estimated $238K.
Alta Wealth Advisors first reported a position in Biogen in Q1 2023 and held it in 5 quarters.
Alta Wealth Advisors's Biogen position peaked at $516K in Q2 2023.
943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Alta Wealth Advisors's 13F filing for Q2 2024, filed 24 Jul 2024.